2021年胰腺癌研究及诊疗新进展

朱鑫哲; 李浩; 徐华祥; 罗国培; 虞先濬

doi:10.19401/j.cnki.1007-3639.2022.01.001

您当前的位置：

首页 >

文章列表页 >

2021年胰腺癌研究及诊疗新进展

专家述评 | 更新时间：2025-12-31

- 2021年胰腺癌研究及诊疗新进展
- Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021
- 中国癌症杂志 2022年32卷第1期页码：1-12
- 作者机构：
  
  复旦大学附属肿瘤医院胰腺外科,复旦大学上海医学院肿瘤学系,复旦大学胰腺肿瘤研究所,上海市胰腺肿瘤研究所,上海 200032
- 作者简介：
  
  [ "虞先濬,主任医师,教授,外科学和肿瘤学双科博士研究生导师,目前担任复旦大学附属肿瘤医院副院长、上海市胰腺肿瘤研究所所长、复旦大学胰腺肿瘤研究所所长、中国抗癌协会胰腺癌专业委员会主任委员。长期从事胰腺肿瘤外科基础和临床转化研究,主要成就有：① 发明“乳头状残端封闭型”胰空肠吻合术,研发专用手术器械,显著提高了手术安全性；② 针对胰腺癌淋巴转移特性,规范手术清扫范围,开展靶向攻击淋巴转移的临床前研究；③ 发现胰腺癌“手术不获益”亚群的临床特征,揭示其分子机制,为建立个体化干预策略奠定基础；④ 发现胰腺癌和胰腺神经内分泌肿瘤增殖与淋巴转移的特殊性,改良国际分期,指导临床决策；⑤ 提出基于间质比例的胰腺癌个体化化疗理论,指导胰腺癌精准治疗。2016年获得国家杰出青年科学基金,2017年入选科技部中青年科技创新领军人才,2019年入选人社部百千万人才工程,2021年获得全国五一劳动奖章。既往主持国家自然科学基金中德国际合作项目1项、区域创新发展联合基金重点项目1项、面上项目2项及省部级项目9项；入选上海市领军人才、上海工匠、上海市新百人计划和上海市启明星跟踪计划。以通信作者（含共同通信作者）在Journal of Clinical Oncology、Gut、Annals of Surgery、Cell Research、Autophagy、Clinical Cancer Research等权威SCI收录期刊上发表论文200余篇。作为第一发明人获得5项国家实用新型专利、上海市优秀发明选拔赛金奖。作为第一完成人获得中国抗癌协会科技奖一等奖、上海医学科技奖一等奖。研究成果受到国内外同行的关注和认可,已被纳入多部胰腺肿瘤临床指南或共识,指导临床实践。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.01.001
  中图分类号： R735.9
- 收稿：2022-01-02，
  
  修回：2022-01-05，
  
  纸质出版：2022-01-30
- 稿件说明：
移动端阅览
朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022,32(1):1-12.

Xinzhe ZHU, Hao LI, Huaxiang XU, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncology, 2022, 32(1): 1-12.
朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022,32(1):1-12. DOI： 10.19401/j.cnki.1007-3639.2022.01.001.

Xinzhe ZHU, Hao LI, Huaxiang XU, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncology, 2022, 32(1): 1-12. DOI： 10.19401/j.cnki.1007-3639.2022.01.001.

摘要

胰腺癌是恶性程度极高的消化道肿瘤

由于缺乏适当的筛查和诊断方法、胰腺位置深、组织活检困难、肿瘤进展快及对治疗应答率低

其发病率与死亡率几乎一致。约80%的患者在确诊时已是晚期

中位生存期不足1年。胰腺癌极具侵袭性的疾病性质和患者的低存活率

使其成为严重的全球疾病负担。大量基础与临床研究的推进

使得胰腺癌在发病机制、诊断方法、围手术期处理、放疗技术和晚期疾病的系统治疗等方面取得了新的进展。这些成果不断丰富胰腺癌患者的诊治手段

改善其预后。现对2021年胰腺癌研究领域的重大研究进展进行综述。

Abstract

Pancreatic cancer is a highly malignant tumor of the digestive tract. Given the lack of appropriate screening and diagnosis methods

the deep location of the pancreas

difficulty in a tissue biopsy

rapid tumor progression and low response rate to radiotherapy or chemotherapy

its morbidity is almost similar to the mortality. Approximately 80% of patients with pancreatic cancer have advanced disease at the time of diagnosis

and the average survival time is less than 1 year. The extremely aggressive nature of pancreatic cancer and the low survival rate make it a heavy global burden. With the advancement of many basic and clinical studies

new progress has been made in the pathogenesis of pancreatic cancer

diagnostic methods

preoperative treatment

radiotherapy techniques and systemic treatment of advanced diseases during the last year. These results further enrich the treatment options for patients with pancreatic cancer and improve the prognosis. The present review summarized the important findings in pancreatic cancer research in 2021.

关键词

Keywords

references

SIEGEL R L , MILLER K D , FUCHS H E , et al. Cancer statistics, 2021 [J ] . CA Cancer J Clin , 2021 , 71 ( 1 ): 7 - 33 . DOI: 10.3322/caac.v71.1 http://doi.org/10.3322/caac.v71.1 https://onlinelibrary.wiley.com/toc/15424863/71/1 https://onlinelibrary.wiley.com/toc/15424863/71/1

CABASAG C J , FERLAY J , LAVERSANNE M , et al. Pancreatic cancer: an increasing global public health concern [J ] . Gut , 2021 . Online ahead of print.

CARIOLI G , MALVEZZI M , BERTUCCIO P , et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer [J ] . Ann Oncol , 2021 , 32 ( 4 ): 478 - 487 . DOI: 10.1016/j.annonc.2021.01.006 http://doi.org/10.1016/j.annonc.2021.01.006 https://linkinghub.elsevier.com/retrieve/pii/S0923753421000144 https://linkinghub.elsevier.com/retrieve/pii/S0923753421000144

SUN D , CAO M , LI H , et al. Cancer burden and trends in China: a review and comparison with Japan and South Korea [J ] . Chin J Cancer Res , 2020 , 32 ( 2 ): 129 - 139 . DOI: 10.21147/j.issn.1000-9604.2020.02.01 http://doi.org/10.21147/j.issn.1000-9604.2020.02.01 http://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2020.02.01?viewType=HTML http://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2020.02.01?viewType=HTML

MIZRAHI J D , SURANA R , VALLE J W , et al. Pancreatic cancer [J ] . Lancet , 2020 , 395 ( 10242 ): 2008 - 2020 . DOI: 10.1016/S0140-6736(20)30974-0 http://doi.org/10.1016/S0140-6736(20)30974-0 https://linkinghub.elsevier.com/retrieve/pii/S0140673620309740 https://linkinghub.elsevier.com/retrieve/pii/S0140673620309740

KLEIN A P . Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors [J ] . Nat Rev Gastroenterol Hepatol , 2021 , 18 ( 7 ): 493 - 502 . DOI: 10.1038/s41575-021-00457-x http://doi.org/10.1038/s41575-021-00457-x https://doi.org/10.1038/s41575-021-00457-x https://doi.org/10.1038/s41575-021-00457-x

MOCCI E , KUNDU P , WHEELER W , et al. Smoking modifies pancreatic cancer risk loci on 2q21.3 [J ] . Cancer Res , 2021 , 81 ( 11 ): 3134 - 3143 . DOI: 10.1158/0008-5472.CAN-20-3267 http://doi.org/10.1158/0008-5472.CAN-20-3267 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3267 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3267

HUANG B Z , PANDOL S J , JEON C Y , et al. New-onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population [J ] . Clin Gastroenterol Hepatol , 2020 , 18 ( 8 ): 1812 - 1821 . e1817. DOI: 10.1016/j.cgh.2019.11.043 http://doi.org/10.1016/j.cgh.2019.11.043 https://linkinghub.elsevier.com/retrieve/pii/S1542356519313837 https://linkinghub.elsevier.com/retrieve/pii/S1542356519313837

CHAN T T , TSE Y K , LUI R N , et al. Fatty pancreas is independently associated with subsequent diabetes mellitus development: a 10-year prospective cohort study [J ] . Clin Gastroenterol Hepatol , 2021 . Online ahead of print.

SCHWARTZ N R M , MATRISIAN L M , SHRADER E E , et al. Potential cost-effectiveness of risk-based pancreatic cancer screening in patients with new-onset diabetes [J ] . J Natl Compr Canc Netw , 2021 : 1 - 9 .

GIRI B , SETHI V , MODI S , et al. Heat shock protein 70 in pancreatic diseases: friend or foe [J ] . J Surg Oncol , 2017 , 116 ( 1 ): 114 - 122 . DOI: 10.1002/jso.v116.1 http://doi.org/10.1002/jso.v116.1 http://doi.wiley.com/10.1002/jso.v116.1 http://doi.wiley.com/10.1002/jso.v116.1

QIAN W , CHEN K , QIN T , et al. The EGFR-HSF 1 axis accelerates the tumorigenesis of pancreatic cancer [J ] . J Exp Clin Cancer Res , 2021 , 40 ( 1 ): 25 . DOI: 10.1186/s13046-020-01823-4 http://doi.org/10.1186/s13046-020-01823-4 https://doi.org/10.1186/s13046-020-01823-4 https://doi.org/10.1186/s13046-020-01823-4

DEL POGGETTO E , HO I L , BALESTRIERI C , et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis [J ] . Science , 2021 , 373 ( 6561 ): eabj0486 . DOI: 10.1126/science.abj0486 http://doi.org/10.1126/science.abj0486 https://www.science.org/doi/10.1126/science.abj0486 https://www.science.org/doi/10.1126/science.abj0486

TSANG E S , TOPHAM J T , KARASINSKA J M , et al. Delving into early-onset pancreatic ductal adenocarcinoma: how does age fit in ?[J ] . Clin Cancer Res , 2021 , 27 ( 1 ): 246 - 254 . DOI: 10.1158/1078-0432.CCR-20-1042 http://doi.org/10.1158/1078-0432.CCR-20-1042 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-20-1042 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-20-1042

OPITZ F V , HAEBERLE L , DAUM A , et al. Tumor microenvironment in pancreatic intraepithelial neoplasia [J ] . Cancers (Basel) , 2021 , 13 ( 24 ): 6188 . DOI: 10.3390/cancers13246188 http://doi.org/10.3390/cancers13246188 https://www.mdpi.com/2072-6694/13/24/6188 https://www.mdpi.com/2072-6694/13/24/6188

HAYASHI A , HONG J , IACOBUZIO-DONAHUE C A . The pancreatic cancer genome revisited [J ] . Nat Rev Gastroenterol Hepatol , 2021 , 18 ( 7 ): 469 - 481 . DOI: 10.1038/s41575-021-00463-z http://doi.org/10.1038/s41575-021-00463-z https://doi.org/10.1038/s41575-021-00463-z https://doi.org/10.1038/s41575-021-00463-z

SIMANSHU D K , NISSLEY D V , MCCORMICK F . RAS proteins and their regulators in human disease [J ] . Cell , 2017 , 170 ( 1 ): 17 - 33 . DOI: 10.1016/j.cell.2017.06.009 http://doi.org/10.1016/j.cell.2017.06.009 https://linkinghub.elsevier.com/retrieve/pii/S0092867417306505 https://linkinghub.elsevier.com/retrieve/pii/S0092867417306505

KRISHNAN T , ROBERTS-THOMSON R , BROADBRIDGE V , et al. Targeting mutated KRAS genes to treat solid tumours [J ] . Mol Diagn Ther , 2021 . Online ahead of print.

CANON J , REX K , SAIKI A Y , et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity [J ] . Nature , 2019 , 575 ( 7781 ): 217 - 223 . DOI: 10.1038/s41586-019-1694-1 http://doi.org/10.1038/s41586-019-1694-1 https://doi.org/10.1038/s41586-019-1694-1 https://doi.org/10.1038/s41586-019-1694-1

SATURNO G , LOPES F , NICULESCU-DUVAZ I , et al. The paradox-breaking PANraf plus src family kinase inhibitor, CCT3833, is effective in mutant KRAS -driven cancers [J ] . Ann Oncol , 2021 , 32 ( 2 ): 269 - 278 . DOI: 10.1016/j.annonc.2020.10.483 http://doi.org/10.1016/j.annonc.2020.10.483 https://linkinghub.elsevier.com/retrieve/pii/S0923753420429862 https://linkinghub.elsevier.com/retrieve/pii/S0923753420429862

WANG J , CHEN Y , HUANG C , et al. Valosin-containing protein stabilizes mutant p 53 to promote pancreatic cancer growth [J ] . Cancer Res , 2021 , 81 ( 15 ): 4041 - 4053 . DOI: 10.1158/0008-5472.CAN-20-3855 http://doi.org/10.1158/0008-5472.CAN-20-3855 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3855 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3855

KASSARDJIAN A , WANG H L . SMAD4-expressing pancreatic ductal adenocarcinomas have better response to neoadjuvant therapy and significantly lower lymph node metastasis rates [J ] . Pancreas , 2020 , 49 ( 9 ): 1153 - 1160 . DOI: 10.1097/MPA.0000000000001636 http://doi.org/10.1097/MPA.0000000000001636 https://journals.lww.com/10.1097/MPA.0000000000001636 https://journals.lww.com/10.1097/MPA.0000000000001636

WANG C , ZHANG T , LIAO Q , et al. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation [J ] . Protein Cell , 2021 , 12 ( 2 ): 128 - 144 . DOI: 10.1007/s13238-020-00760-4 http://doi.org/10.1007/s13238-020-00760-4 https://doi.org/10.1007/s13238-020-00760-4 https://doi.org/10.1007/s13238-020-00760-4

GRANT R C , DENROCHE R , JANG G H , et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma [J ] . Gut , 2021 , 70 ( 10 ): 1894 - 1903 . DOI: 10.1136/gutjnl-2020-320730 http://doi.org/10.1136/gutjnl-2020-320730 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320730 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320730

HSU F C , ROBERTS N J , CHILDS E , et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene [J ] . JAMA Oncol , 2021 , 7 ( 11 ): 1664 - 1668 . DOI: 10.1001/jamaoncol.2021.3701 http://doi.org/10.1001/jamaoncol.2021.3701 https://jamanetwork.com/journals/jamaoncology/fullarticle/2783767 https://jamanetwork.com/journals/jamaoncology/fullarticle/2783767

SCARPA A , REAL F X , LUCHINI C . Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management [J ] . Gut , 2018 , 67 ( 9 ): 1561 - 1563 . DOI: 10.1136/gutjnl-2018-316151 http://doi.org/10.1136/gutjnl-2018-316151 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316151 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316151

FUJIKURA K , HOSODA W , FELSENSTEIN M , et al. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF 4 mutations predominantly in low-grade regions [J ] . Gut , 2021 , 70 ( 5 ): 928 - 939 . DOI: 10.1136/gutjnl-2020-321217 http://doi.org/10.1136/gutjnl-2020-321217 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-321217 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-321217

GUPTA V K , SHARMA N S , DURDEN B , et al. Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune evasion in pancreatic cancer [J ] . Cancer Res , 2021 , 81 ( 15 ): 4001 - 4013 . DOI: 10.1158/0008-5472.CAN-20-2562 http://doi.org/10.1158/0008-5472.CAN-20-2562 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-2562 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-2562

MEHRA S , DESHPANDE N , NAGATHIHALLI N . Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress [J ] . Cancers (Basel) , 2021 , 13 ( 17 ): 4434 . DOI: 10.3390/cancers13174434 http://doi.org/10.3390/cancers13174434 https://www.mdpi.com/2072-6694/13/17/4434 https://www.mdpi.com/2072-6694/13/17/4434

BIANCUR D E , KAPNER K S , YAMAMOTO K , et al. Functional genomics identifies metabolic vulnerabilities in pancreatic cancer [J ] . Cell Metab , 2021 , 33 ( 1 ): 199 - 210 . e198. DOI: 10.1016/j.cmet.2020.10.018 http://doi.org/10.1016/j.cmet.2020.10.018 https://linkinghub.elsevier.com/retrieve/pii/S1550413120305519 https://linkinghub.elsevier.com/retrieve/pii/S1550413120305519

HU Q , QIN Y , JI S , et al. MTAP deficiency-induced metabolic reprogramming creates a vulnerability to cot argeting de novo purine synthesis and glycolysis in pancreatic cancer [J ] . Cancer Res , 2021 , 81 ( 19 ): 4964 - 4980 . DOI: 10.1158/0008-5472.CAN-20-0414 http://doi.org/10.1158/0008-5472.CAN-20-0414 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-0414 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-0414

TSAI P Y , LEE M S , JADHAV U , et al. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by MTORC1 [J ] . Proc Natl Acad Sci U S A , 2021 , 118 ( 10 ): e2003014118.

HOSEIN A N , BREKKEN R A , MAITRA A . Pancreatic cancer stroma: an update on therapeutic targeting strategies [J ] . Nat Rev Gastroenterol Hepatol , 2020 , 17 ( 8 ): 487 - 505 . DOI: 10.1038/s41575-020-0300-1 http://doi.org/10.1038/s41575-020-0300-1 https://doi.org/10.1038/s41575-020-0300-1 https://doi.org/10.1038/s41575-020-0300-1

HO W J , JAFFEE E M , ZHENG L . The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities [J ] . Nat Rev Clin Oncol , 2020 , 17 ( 9 ): 527 - 540 . DOI: 10.1038/s41571-020-0363-5 http://doi.org/10.1038/s41571-020-0363-5 https://doi.org/10.1038/s41571-020-0363-5 https://doi.org/10.1038/s41571-020-0363-5

TAKAHASHI R , MACCHINI M , SUNAGAWA M , et al. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression [J ] . Gut , 2021 , 70 ( 2 ): 330 - 341 .

GRÜNWALD B T , DEVISME A , ANDRIEUX G , et al. Spatially confined sub-tumor microenvironments in pancreatic cancer [J ] . Cell , 2021 , 184 ( 22 ): 5577 - 5592 . e5518. DOI: 10.1016/j.cell.2021.09.022 http://doi.org/10.1016/j.cell.2021.09.022 https://linkinghub.elsevier.com/retrieve/pii/S0092867421011053 https://linkinghub.elsevier.com/retrieve/pii/S0092867421011053

SCHOEPS B , ECKFELD C , PROKOPCHUK O , et al. TIMP1 triggers neutrophil extracellular trap formation in pancreatic cancer [J ] . Cancer Res , 2021 , 81 ( 13 ): 3568 - 3579 . DOI: 10.1158/0008-5472.CAN-20-4125 http://doi.org/10.1158/0008-5472.CAN-20-4125 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-4125 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-4125

SERRANO-POZO A , DAS S , HYMAN B T . APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches [J ] . Lancet Neurol , 2021 , 20 ( 1 ): 68 - 80 . DOI: 10.1016/S1474-4422(20)30412-9 http://doi.org/10.1016/S1474-4422(20)30412-9 https://linkinghub.elsevier.com/retrieve/pii/S1474442220304129 https://linkinghub.elsevier.com/retrieve/pii/S1474442220304129

KEMP S B , CARPENTER E S , STEELE N G , et al. Apolipoprotein e promotes immune suppression in pancreatic cancer through NF-κB-mediated production of CXCL1 [J ] . Cancer Res , 2021 , 81 ( 16 ): 4305 - 4318 . DOI: 10.1158/0008-5472.CAN-20-3929 http://doi.org/10.1158/0008-5472.CAN-20-3929 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3929 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3929

LIU H , SHI Y , QIAN F . Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts [J ] . Adv Drug Deliv Rev , 2021 , 172 : 37 - 51 . DOI: 10.1016/j.addr.2021.02.012 http://doi.org/10.1016/j.addr.2021.02.012 https://linkinghub.elsevier.com/retrieve/pii/S0169409X21000582 https://linkinghub.elsevier.com/retrieve/pii/S0169409X21000582

HUTTON C , HEIDER F , BLANCO-GOMEZ A , et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity [J ] . Cancer Cell , 2021 , 39 ( 9 ): 1227 - 1244 . e1220. DOI: 10.1016/j.ccell.2021.06.017 http://doi.org/10.1016/j.ccell.2021.06.017 https://linkinghub.elsevier.com/retrieve/pii/S1535610821003391 https://linkinghub.elsevier.com/retrieve/pii/S1535610821003391

LI T J , LI H , ZHANG W H , et al. Human splenic ter cells: a relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma [J ] . Int J Cancer , 2021 , 148 ( 7 ): 1756 - 1767 . DOI: 10.1002/ijc.v148.7 http://doi.org/10.1002/ijc.v148.7 https://onlinelibrary.wiley.com/toc/10970215/148/7 https://onlinelibrary.wiley.com/toc/10970215/148/7

CAO L , HUANG C , CUI ZHOU D , et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma [J ] . Cell , 2021 , 184 ( 19 ): 5031 - 5052 . e5026. DOI: 10.1016/j.cell.2021.08.023 http://doi.org/10.1016/j.cell.2021.08.023 https://linkinghub.elsevier.com/retrieve/pii/S0092867421009971 https://linkinghub.elsevier.com/retrieve/pii/S0092867421009971

LUO G , JIN K , DENG S , et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter [J ] . Biochim Biophys Acta Rev Cancer , 2021 , 1875 ( 2 ): 188409 . DOI: 10.1016/j.bbcan.2020.188409 http://doi.org/10.1016/j.bbcan.2020.188409 https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301281 https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301281

SINGHI A D , WOOD L D . Early detection of pancreatic cancer using DNA-based molecular approaches [J ] . Nat Rev Gastroenterol Hepatol , 2021 , 18 ( 7 ): 457 - 468 .

MAJUMDER S , TAYLOR W R , FOOTE P H , et al. High detection rates of pancreatic cancer across stages by plasma assay of novel methylated DNA markers and CA19-9 [J ] . Clin Cancer Res , 2021 , 27 ( 9 ): 2523 - 2532 . DOI: 10.1158/1078-0432.CCR-20-0235 http://doi.org/10.1158/1078-0432.CCR-20-0235 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-20-0235 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-20-0235

DINGES S S , HOHM A , VANDERGRIFT L A , et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations [J ] . Nat Rev Urol , 2019 , 16 ( 6 ): 339 - 362 . DOI: 10.1038/s41585-019-0185-3 http://doi.org/10.1038/s41585-019-0185-3 https://doi.org/10.1038/s41585-019-0185-3 https://doi.org/10.1038/s41585-019-0185-3

DE MATTEIS S , BONAFÈ M , GIUDETTI A M . Urinary metabolic biomarkers in cancer patients: an overview [J ] . Methods Mol Biol , 2021 , 2292 : 203 - 212 .

RADON T P , MASSAT N J , JONES R , et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma [J ] . Clin Cancer Res , 2015 , 21 ( 15 ): 3512 - 3521 . DOI: 10.1158/1078-0432.CCR-14-2467 http://doi.org/10.1158/1078-0432.CCR-14-2467 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-14-2467 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-14-2467

YANG K S , CIPRANI D , O’SHEA A , et al. Extracellular vesicle analysis allows for identification of invasive IPMN [J ] . Gastroenterology , 2021 , 160 ( 4 ): 1345 - 1358 . e1311. DOI: 10.1053/j.gastro.2020.11.046 http://doi.org/10.1053/j.gastro.2020.11.046 https://linkinghub.elsevier.com/retrieve/pii/S0016508520355153 https://linkinghub.elsevier.com/retrieve/pii/S0016508520355153

MILLIKAN K W , DEZIEL D J , SILVERSTEIN J C , et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas [J ] . Am Surg , 1999 , 65 ( 7 ): 618-623; discussion 623 - 624 .

VAN DER HEIJDE N , LOF S , BUSCH O R , et al. Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy [J ] . Surgery , 2021 . Online ahead of print .

KLOMPMAKER S , DE ROOIJ T , KOERKAMP B G , et al. International validation of reduced major morbidity after minimally invasive distal pancreatectomy compared with open pancreatectomy [J ] . Ann Surg , 2021 , 274 ( 6 ): e966-e973 .

DE ROOIJ T , VAN HILST J , VAN SANTVOORT H , et al. Minimally invasive versus open distal pancreatectomy (leopard) a multicenter patient-blinded randomized controlled trial [J ] . Ann Surg , 2019 , 269 ( 1 ): 2 - 9 . DOI: 10.1097/SLA.0000000000002979 http://doi.org/10.1097/SLA.0000000000002979 https://journals.lww.com/00000658-201901000-00002 https://journals.lww.com/00000658-201901000-00002

ZHANG J , SANS M , GARZA K Y , et al. Mass spectrometry technologies to advance care for cancer patients in clinical and intraoperative use [J ] . Mass Spectrom Rev , 2021 , 40 ( 5 ): 692 - 720 . DOI: 10.1002/mas.v40.5 http://doi.org/10.1002/mas.v40.5 https://onlinelibrary.wiley.com/toc/10982787/40/5 https://onlinelibrary.wiley.com/toc/10982787/40/5

KING M E , ZHANG J , LIN J Q , et al. Rapid diagnosis and tumor margin assessment during pancreatic cancer surgery with the masspec pen technology [J ] . Proc Natl Acad Sci U S A , 2021 , 118 ( 28 ): e2104411118.

KUNZMANN V , SIVEKE J T , ALGÜL H , et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial [J ] . Lancet Gastroenterol Hepatol , 2021 , 6 ( 2 ): 128 - 138 . DOI: 10.1016/S2468-1253(20)30330-7 http://doi.org/10.1016/S2468-1253(20)30330-7 https://linkinghub.elsevier.com/retrieve/pii/S2468125320303307 https://linkinghub.elsevier.com/retrieve/pii/S2468125320303307

DAHAN L , WILLIET N , LE MALICOT K , et al. Randomized phase Ⅱ trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the panoptimox-prodige 35 trial [J ] . J Clin Oncol , 2021 , 39 ( 29 ): 3242 - 3250 . DOI: 10.1200/JCO.20.03329 http://doi.org/10.1200/JCO.20.03329 https://ascopubs.org/doi/10.1200/JCO.20.03329 https://ascopubs.org/doi/10.1200/JCO.20.03329

SOHAL D P , WALSH R M , RAMANATHAN R K , et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy [J ] . J Natl Cancer Inst , 2014 , 106 ( 3 ): dju011 . DOI: 10.1093/jnci/dju011 http://doi.org/10.1093/jnci/dju011 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju011 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju011

SOHAL D P S , DUONG M , AHMAD S A , et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial [J ] . JAMA Oncol , 2021 , 7 ( 3 ): 421 - 427 . DOI: 10.1001/jamaoncol.2020.7328 http://doi.org/10.1001/jamaoncol.2020.7328 https://jamanetwork.com/journals/jamaoncology/fullarticle/2775174 https://jamanetwork.com/journals/jamaoncology/fullarticle/2775174

HECHT J R , LONARDI S , BENDELL J , et al. Randomized phase Ⅲ study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (sequoia) [J ] . J Clin Oncol , 2021 , 39 ( 10 ): 1108 - 1118 . DOI: 10.1200/JCO.20.02232 http://doi.org/10.1200/JCO.20.02232 https://ascopubs.org/doi/10.1200/JCO.20.02232 https://ascopubs.org/doi/10.1200/JCO.20.02232

ROJAS L A , BALACHANDRAN V P . Scaling the immune incline in PDAC [J ] . Nat Rev Gastroenterol Hepatol , 2021 , 18 ( 7 ): 453 - 454 .

VONDERHEIDE R H . CD 40 agonist antibodies in cancer immunotherapy [J ] . Annu Rev Med , 2020 , 71 : 47 - 58 . DOI: 10.1146/med.2020.71.issue-1 http://doi.org/10.1146/med.2020.71.issue-1 https://www.annualreviews.org/toc/med/71/1 https://www.annualreviews.org/toc/med/71/1

O’HARA M H , O’REILLY E M , ROSEMARIE M , et al. A phase ib study of cd40 agonistic monoclonal antibody apx005m together with gemcitabine (GEM) and nab-paclitaxel (NP) with or without nivolumab (nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients [J ] . Cancer Res , 2019 , 79 ( 13 ): 3 . DOI: 10.1158/0008-5472.CAN-18-3552 http://doi.org/10.1158/0008-5472.CAN-18-3552 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-18-3552 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-18-3552

JIANG H , COURAU T , BORISON J , et al. Activating immune recognition in pancreatic ductal adenocarcinoma via autophagy inhibition, mek blockade, and CD40 agonism [J ] . Gastroenterology , 2021 . Online ahead of print.

MARELLI G , CHARD DUNMALL L S , YUAN M , et al. A systemically deliverable vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer [J ] . J Immunother Cancer , 2021 , 9 ( 1 ): e001624 . DOI: 10.1136/jitc-2020-001624 http://doi.org/10.1136/jitc-2020-001624 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-001624 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-001624

MELISI D , OH D Y , HOLLEBECQUE A , et al. Safety and activity of the TGF-β receptor Ⅰ kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer [J ] . J Immunother Cancer , 2021 , 9 ( 3 ): e002068 . DOI: 10.1136/jitc-2020-002068 http://doi.org/10.1136/jitc-2020-002068 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002068 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002068

ANWAR M Y , WILLIAMS G R , PALURI R K . CAR-T cell therapy in pancreaticobiliary cancers: a focused review of clinical data [J ] . J Gastrointest Cancer , 2021 , 52 ( 1 ): 1 - 10 . DOI: 10.1007/s12029-020-00457-1 http://doi.org/10.1007/s12029-020-00457-1 https://doi.org/10.1007/s12029-020-00457-1 https://doi.org/10.1007/s12029-020-00457-1

LESCH S , BLUMENBERG V , STOIBER S , et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours [J ] . Nat Biomed Eng , 2021 , 5 ( 11 ): 1246 - 1260 . DOI: 10.1038/s41551-021-00737-6 http://doi.org/10.1038/s41551-021-00737-6 https://doi.org/10.1038/s41551-021-00737-6 https://doi.org/10.1038/s41551-021-00737-6

GOOD C R , AZNAR M A , KURAMITSU S , et al. An NK-like CAR-T cell transition in CAR-T cell dysfunction [J ] . Cell , 2021 , 184 ( 25 ): 6081 - 6100 . e6026. DOI: 10.1016/j.cell.2021.11.016 http://doi.org/10.1016/j.cell.2021.11.016 https://linkinghub.elsevier.com/retrieve/pii/S0092867421013313 https://linkinghub.elsevier.com/retrieve/pii/S0092867421013313

ALI A I , WANG M , VON SCHEIDT B , et al. A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer [J ] . Clin Cancer Res , 2021 , 27 ( 22 ): 6222 - 6234 . DOI: 10.1158/1078-0432.CCR-21-1141 http://doi.org/10.1158/1078-0432.CCR-21-1141 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-21-1141 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-21-1141

PETRELLI F , COMITO T , GHIDINI A , et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials [J ] . Int J Radiat Oncol Biol Phys , 2017 , 97 ( 2 ): 313 - 322 . DOI: 10.1016/j.ijrobp.2016.10.030 http://doi.org/10.1016/j.ijrobp.2016.10.030 https://linkinghub.elsevier.com/retrieve/pii/S0360301616333776 https://linkinghub.elsevier.com/retrieve/pii/S0360301616333776

MAHADEVAN A , MONINGI S , GRIMM J , et al. Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer [J ] . Int J Radiat Oncol Biol Phys , 2021 , 110 ( 1 ): 206 - 216 . DOI: 10.1016/j.ijrobp.2020.11.017 http://doi.org/10.1016/j.ijrobp.2020.11.017 https://linkinghub.elsevier.com/retrieve/pii/S0360301620345399 https://linkinghub.elsevier.com/retrieve/pii/S0360301620345399

MUELLER A C , PIPER M , GOODSPEED A , et al. Induction of ADAM10 by radiation therapy drives fibrosis, resistance, and epithelial-to-mesenchyal transition in pancreatic cancer [J ] . Cancer Res , 2021 , 81 ( 12 ): 3255 - 3269 . DOI: 10.1158/0008-5472.CAN-20-3892 http://doi.org/10.1158/0008-5472.CAN-20-3892 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3892 http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-3892

REYNGOLD M , O’REILLY E M , VARGHESE A M , et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer [J ] . JAMA Oncol , 2021 , 7 ( 5 ): 735 - 738 . DOI: 10.1001/jamaoncol.2021.0057 http://doi.org/10.1001/jamaoncol.2021.0057 https://jamanetwork.com/journals/jamaoncology/fullarticle/2777063 https://jamanetwork.com/journals/jamaoncology/fullarticle/2777063

ZHU X , CAO Y , LIU W , et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 8 ): 1093 - 1102 . DOI: 10.1016/S1470-2045(21)00286-2 http://doi.org/10.1016/S1470-2045(21)00286-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002862 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002862

ARVIND R , CHANDANA S R , BORAD M J , et al. Tumor-treating fields: a fourth modality in cancer treatment, new practice updates [J ] . Crit Rev Oncol Hematol , 2021 , 168 : 103535 . DOI: 10.1016/j.critrevonc.2021.103535 http://doi.org/10.1016/j.critrevonc.2021.103535 https://linkinghub.elsevier.com/retrieve/pii/S104084282100322X https://linkinghub.elsevier.com/retrieve/pii/S104084282100322X

RIVERA F , BENAVIDES M , GALLEGO J , et al. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the panova phase 2 study [J ] . Pancreatology , 2019 , 19 ( 1 ): 64 - 72 . DOI: 10.1016/j.pan.2018.10.004 http://doi.org/10.1016/j.pan.2018.10.004 https://linkinghub.elsevier.com/retrieve/pii/S1424390318306987 https://linkinghub.elsevier.com/retrieve/pii/S1424390318306987

BAI L , PFEIFER T , GROSS W , et al. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer [J ] . Front Oncol , 2021 , 11 : 738801 . DOI: 10.3389/fonc.2021.738801 http://doi.org/10.3389/fonc.2021.738801 https://www.frontiersin.org/articles/10.3389/fonc.2021.738801/full https://www.frontiersin.org/articles/10.3389/fonc.2021.738801/full

浏览量

4318

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2018年胰腺癌研究及诊疗新进展

2017年胰腺癌基础研究及诊疗新进展

2016年胰腺癌研究及诊疗进展

2015年胰腺癌研究及诊疗前沿进展

2024年胰腺癌研究及诊疗新进展